On Thursday, iBio, Inc. (NYSE:IBIO) expanded its cardiometabolic and obesity treatment development program by in-licensing a potentially long-acting anti-myostatin antibody from AstralBio ...

Ofran refers to them as “nano-robots.” The new AU-007 antibody treatment is the first computer-designed antibody to enter a human trial, he said. It was designed by artificial intelligence ...

The complementary Genovac Nano platform constitutes screening of a much greater number of plasma cells to increase the chances for identification of specific antibodies against challenging targets ...

Peer has tested the injected drug on mice, found it as effective as familiar antibody treatments, and outlined the achievement in the peer-reviewed journal Nature Nanotechnology. The technology ...

This new therapy works by bringing a nanoparticle filled with a cancer-fighting drug straight to the tumor site, while antibodies attached to the nanoparticle bind to two different proteins (CD47 ...

Additionally, the combined nano-antibodies worked even when tested on a virus variant that mutates extremely quickly. "This means that the risk is very small that the virus would become resistant ...

clinical-stage biopharmaceutical company with a next-generation proprietary modular antibody-drug conjugate (ADC)-like, nano-immunoconjugates (NIC) platform. Upon completion of the Proposed Merger ...